Calamos Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.57M Sell
65,212
-2,171
-3% -$56.8K 0.05% 166
2026
Q1
$1.89M Buy
67,383
+3,188
+5% +$84.9K 0.07% 148
2025
Q4
$1.6M Buy
64,195
+703
+1% +$17.7K 0.06% 147
2025
Q3
$1.62M Sell
63,492
-268
-0.4% -$6.62K 0.06% 147
2025
Q2
$1.55M Sell
63,760
-1,361
-2% -$31.7K 0.07% 134
2025
Q1
$1.65M Buy
65,121
+12,647
+24% +$331K 0.08% 112
2024
Q4
$1.39M Buy
52,474
+469
+0.9% +$12.7K 0.07% 119
2024
Q3
$1.51M Sell
52,005
-80
-0.2% -$2.33K 0.08% 121
2024
Q2
$1.46M Sell
52,085
-2,885
-5% -$79.4K 0.08% 118
2024
Q1
$1.53M Buy
54,970
+460
+0.8% +$12.8K 0.09% 117
2023
Q4
$1.57M Sell
54,510
-9,760
-15% -$295K 0.1% 108
2023
Q3
$2.13M Sell
64,270
-1,795
-3% -$63.5K 0.16% 90
2023
Q2
$2.42M Sell
66,065
-1,285
-2% -$50K 0.18% 91
2023
Q1
$2.75M Sell
67,350
-30
-0% -$1.3K 0.22% 85
2022
Q4
$3.45M Sell
67,380
-608
-0.9% -$29.1K 0.27% 83
2022
Q3
$2.98M Sell
67,988
-2,637
-4% -$128K 0.26% 80
2022
Q2
$3.7M Buy
70,625
+4,956
+8% +$253K 0.33% 73
2022
Q1
$3.4M Buy
65,669
+325
+0.5% +$16.9K 0.25% 85
2021
Q4
$3.86M Sell
65,344
-1,106
-2% -$54.8K 0.28% 81
2021
Q3
$2.86M Sell
66,450
-2,391
-3% -$106K 0.23% 86
2021
Q2
$2.7M Buy
68,841
+1,766
+3% +$68.7K 0.21% 91
2021
Q1
$2.43M Sell
67,075
-1,555
-2% -$55.2K 0.2% 91
2020
Q4
$2.53M Buy
68,630
+39,437
+135% +$1.45M 0.23% 78
2020
Q3
$1.02M Sell
29,193
-5,098
-15% -$179K 0.12% 125
2020
Q2
$1.06M Sell
34,291
-10,152
-23% -$345K 0.13% 106
2020
Q1
$1.38M Sell
44,443
-135,155
-75% -$4.61M 0.21% 73
2019
Q4
$6.68M Buy
179,598
+643
+0.4% +$22.9K 0.79% 30
2019
Q3
$6.1M Buy
178,955
+2,803
+2% +$102K 0.82% 31
2019
Q2
$7.24M Buy
176,152
+2,117
+1% +$84.1K 0.98% 24
2019
Q1
$7.01M Buy
174,035
+52,299
+43% +$2.09M 1% 21
2018
Q4
$5.04M Buy
121,736
+3,935
+3% +$163K 0.76% 35
2018
Q3
$4.93M Buy
117,801
+472
+0.4% +$18.2K 0.61% 51
2018
Q2
$4.04M Sell
117,329
-3,106
-3% -$106K 0.5% 63
2018
Q1
$4.06M Buy
120,435
+2,180
+2% +$74.9K 0.51% 66
2017
Q4
$4.06M Sell
118,255
-2,332
-2% -$79.5K 0.53% 63
2017
Q3
$4.08M Buy
120,587
+1,644
+1% +$52.8K 0.57% 59
2017
Q2
$3.79M Sell
118,943
-17,045
-13% -$538K 0.54% 56
2017
Q1
$4.41M Sell
135,988
-69,109
-34% -$2.18M 0.66% 47
2016
Q4
$6.32M Buy
205,097
+26,202
+15% +$800K 1.02% 22
2016
Q3
$5.75M Buy
178,895
+13,804
+8% +$462K 0.98% 24
2016
Q2
$5.51M Buy
165,091
+14,232
+9% +$454K 0.97% 28
2016
Q1
$4.24M Buy
150,859
+14,696
+11% +$420K 0.82% 31
2015
Q4
$4.17M Buy
136,163
+4,388
+3% +$138K 0.83% 29
2015
Q3
$3.93M Buy
131,775
+4,001
+3% +$128K 0.94% 27
2015
Q2
$4.07M Buy
127,774
+8,125
+7% +$265K 0.96% 25
2015
Q1
$3.95M Buy
119,649
+11,308
+10% +$360K 0.99% 23
2014
Q4
$3.2M Buy
108,341
+48,904
+82% +$1.4M 0.92% 22
2014
Q3
$1.67M Buy
59,437
+1,897
+3% +$53.2K 0.48% 84
2014
Q2
$1.62M Sell
57,540
-8,207
-12% -$234K 0.46% 85
2014
Q1
$2M Buy
65,747
+2,509
+4% +$74.8K 0.59% 64
2013
Q4
$1.84M Buy
63,238
+8,622
+16% +$251K 0.56% 71
2013
Q3
$1.49M Buy
+54,616
New +$1.49M 0.49% 85

Other funds holding PFE

Calamos Wealth Management's PFE Position: Q2 2026 in Review

Calamos Wealth Management reduced its Pfizer (PFE) stake by 3.2% in Q2 2026, selling an estimated $56.8K and leaving 65,212 shares worth $1.57M. The position accounts for 0.05% of the portfolio, ranked #166.

Calamos Wealth Management first reported a position in PFE in Q3 2013 and has held it in 52 quarters since. The position peaked at $7.24M in Q2 2019. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Calamos Wealth Management held 65,212 shares of Pfizer worth $1.57M as of Q2 2026.
  • Calamos Wealth Management sold 2,171 Pfizer shares in Q2 2026, an estimated $56.8K.
  • Pfizer made up 0.05% of Calamos Wealth Management's portfolio in Q2 2026, its #166 holding.
  • Calamos Wealth Management first reported a position in Pfizer in Q3 2013 and has held it in 52 quarters since.
  • Calamos Wealth Management's Pfizer position peaked at $7.24M in Q2 2019.
  • 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.